Necitumumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | EGFR |
| Clinical data | |
| Identifiers | |
906805-06-9  | |
| None | |
| UNII |
2BT4C47RUI  |
| KEGG |
D10018 |
| Chemical data | |
| Formula | C6436H9958N1702O2020S42 |
| 144.84 kDa | |
| (what is this?) (verify) | |
Necitumumab (proposed INN) is a monoclonal antibody and an antineoplastic. It binds to the epidermal growth factor receptor (EGFR).[1] As of October 2009, two Phase III clinical trials are planned to investigate its effects on non-small cell lung carcinoma.[2][3]
References
- ↑ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
- ↑ Clinical trial number NCT00981058 for "Squamous Non-Small Cell Lung Cancer (NSCLC) Treatment With the Inhibitor of Epidermal Growth Factor Receptor (EGFR) (SQUIRE)" at ClinicalTrials.gov
- ↑ Clinical trial number NCT00982111 for "NonSquamous Non-Small Cell Lung Cancer Treatment With the Inhibitor of Epidermal Growth Factor Receptor (INSPIRE)" at ClinicalTrials.gov